Ownership and insider activity for Spero Therapeutics, Inc. (SPRO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases within the United States.
Price
| Price | $1.11 |
| Market Cap | $64M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-03 | Zack Debra | A-Award | 324,675 | $500K |
| 2026-08-03 | Zack Debra | A-Award | 162,311 | |
| 2026-08-03 | Zack Debra | |||
| 2026-06-23 | Deshpande Milind | A-Award | 10,000 | |
| 2026-06-23 | Deshpande Milind | A-Award | 20,000 | $43K |
| 2026-06-23 | Tregoning Kathleen | A-Award | 10,000 | |
| 2026-06-23 | Tregoning Kathleen | A-Award | 20,000 | $43K |
| 2026-06-23 | Smith Cynthia | A-Award | 10,000 | |
| 2026-06-23 | Smith Cynthia | A-Award | 20,000 | $43K |
| 2026-06-23 | VINK PATRICK V.J.J. | A-Award | 10,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.3M | $87.3M | $34.1M | $29.7M | $85.2M | $112.6M | $109.1M | $76.3M | $52.9M | $40.3M |
| Short-term Investments | 0 | 0 | $81.4M | $52.3M | $41.7M | $33.8M | 0 | 0 | 0 | 0 |
| Receivables | $304000 | $2.9M | $1.3M | $10.2M | 0 | $2.6M | $1.1M | $50.7M | $52.5M | $25.4M |
| Inventory | 0 | -$4.8M | -$8.8M | 0 | 0 | 0 | -$4.5M | 0 | 0 | 0 |
| Total Current Assets | $11.9M | $87.3M | $115.4M | $95.4M | $139.1M | $157.9M | $109.1M | $131.2M | $107.3M | $67.3M |
| Property, Plant & Equipment | $1.5M | $1.2M | $2.9M | $7.1M | $8.8M | $7.6M | $5.5M | $4.2M | $3.1M | $1.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $13.8M | $93.5M | $129.0M | $106.1M | $153.5M | $171.1M | $124.8M | $182.4M | $110.5M | $68.9M |
| Accounts Payable | $1.1M | $3.5M | $3.6M | $4.1M | $1.2M | $1.1M | $617000 | $1.4M | $7.3M | $693000 |
| Short-term Debt | 0 | 0 | 0 | $928000 | 0 | 0 | $1.7M | $1.7M | $1.7M | $2.0M |
| Total Current Liabilities | $6.9M | $8.2M | $12.3M | $26.7M | $14.3M | $18.7M | $21.6M | $37.2M | $49.1M | $8.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $7.4M | $8.5M | $13.2M | $31.5M | $21.4M | $82.8M | $48.9M | $75.5M | $64.4M | $9.9M |
| Retained Earnings | -$45.4M | -$96.8M | -$138.5M | -$199.4M | -$277.7M | -$367.5M | -$413.9M | -$391.1M | -$459.6M | -$451.1M |
| Total Equity | $10.2M | $85.0M | $115.9M | $74.6M | $132.0M | $88.3M | $75.9M | $106.9M | $46.1M | $59.0M |
| Total Debt | 0 | 0 | 0 | $5.5M | $7.8M | $7.3M | $6.6M | $5.5M | $4.3M | $2.9M |
| Net Debt | -$10.3M | -$87.3M | -$115.4M | -$76.5M | -$119.1M | -$139.1M | -$102.5M | -$70.8M | -$48.6M | -$37.4M |
| Working Capital | $5.0M | $79.1M | $103.1M | $68.8M | $124.8M | $139.2M | $87.5M | $94.1M | $58.2M | $58.4M |
Financial Health
| Debt / Equity | 0.05 |
| Current Ratio | 6.12 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 0.63 |
Profitability
| Return on Equity | 16.17% |
| Return on Invested Capital | 12.56% |
| Return on Assets | 13.99% |
| Gross Margin | 100.00% |
| Operating Margin | 14.02% |
| Net Margin | 17.18% |
Related companies: ABOS · ACTU · CGTX · CRBP · HURA · INO · IRD
Explore sector: Healthcare · Biotechnology
More sections of SPRO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks